Probe Biotech’s Diverse Subsectors for Strong, Undervalued Companies: Van Leeuwenhoeck’s Marcel Wijma
July 01, 2015 at 04:00 AM EDT
The Life Sciences Report: Marcel, you cover a wide range of life sciences companies that are developing tools, diagnostics, pharmaceuticals and regenerative therapies. What does being involved in each of these subsectors lend to . . . → Read More: Probe Biotech’s Diverse Subsectors for Strong, Undervalued Companies: Van Leeuwenhoeck’s Marcel Wijma Similar Articles: An Undervalued Biotech Is Testing the Cure for Cancer Now, and Chen Lin Wants In Stock Update (NASDAQ:YHOO): Starboard says Yahoo remains deeply undervalued Where Do Cures Reside? Morrie Ruffin and Michael Werner of the Alliance for Regenerative Medicine Think the Answer Is in Regenerative Medicine